reveal marked divergence over time from the normal control. At post-mortem, diaphragmatic morphometry shows that in the untreated dystrophic dog, the ratio of length-to-width at fi xed sarcomere length is 15+/-8% of control at one year of age, providing a robust primary endpoint for investigational therapy. Cardiac mechanics, as studied in detail by isolated organ perfusion, undergo near complete loss in dystrophic dogs of both the Frank/Starling mechanism and adrenergic inotropic responsiveness by one year of age. Clinical and histological indices of myodegeneration correlate strongly with the pattern of muscle and myofi ber-specifi c expression of myosin isoforms, especially in Myh16+ fi bers from the mandibular elevators. We have most recently precision-mapped the deletion endpoints fl anking the entire dystrophin coding sequence in a second canine DMD model, "GSHPMD", and have developed a plan to use this unique resource to rigorously assess the risk of deleterious autoimmunity following systemic gene therapy with AAV9-dystrophin and AAV9-utrophin.
INTRODUCTION:
Highly compacted DNA nanoparticles, composed of single molecules of plasmid DNA compacted with block copolymers of polyethylene glycol and poly-L-lysine (CK30PEG), represent a promising non-viral technology that has demonstrated remarkable effectiveness in delivering genes to the brain, eyes and lungs with minimal toxicity and immunogenicity. With the growing knowledge of the complex genetic alterations and subtypes in Glioblastoma (GBM), modulation of defective and malfunctioning genes, cellular pathways, and the tumor microenvironment is increasingly viewed as a promising approach. The clinical development of non-viral vectors has been hindered in part by relatively low gene transfer effi ciencies compared to viral vectors. This may be due to the inability to tolerate or overcome various biological barriers. A particularly challenging barrier involves endo-lysosomal traffi cking within cells, where therapeutic DNA is often degraded in the acidic and enzyme-rich late endosomes and lysosomes before reaching the nucleus. To overcome this potential shortcoming, we engineered a pH-responsive DNA nanoparticle platform designed to protect DNA from degradation in vivo, enable efficient intracellular trafficking and transgene expression, and tested the ability of this system to knockdown a model gene in brain tumors.
METHODS:
A copolymer containing 5 kDa polyethylene glycol, 18-mer poly-L-lysine, and 12-mer poly-L-histidine, CH12K18PEG5k, was chosen based on nanoparticle physicochemical characteristics and DNA protection. Using this polymer, DNA nanoparticles were formulated using a reporter plasmid (GFP, shLuciferase RNAi). GL261 mouse glioma cells were stably transfected with the fi refl y luciferase gene to enable in vivo bioluminescent imaging of a tumor-specifi c transgene (Xenogen IVIS). DNA nanoparticles were directly applied to glioma cells in culture and to intracranial tumors in vivo. Intracellular traffi cking of nanoparticles in glioma cells were performed using fl uorescently-labeled DNA nanoparticles, endosome-specifi c labeling dyes, and endocytic pathway inhibition agents.
RESULTS and DISCUSSION: CH12K18PEG5k compacted DNA into rod-shaped DNA nanoparticles with similar morphology and colloidal stability as CK30PEG DNA nanoparticles. Intracellular traffi cking and uptake inhibition experiments revealed clathrin-dependent endocytosis (CME) as the primary pathway for DNA nanoparticle internalization in brain tumor cells. CH12K18PEG5k DNA nanoparticles effi ciently protected plasmid DNA from both DNase-mediated and acidic lysosomal degradation. CH12K18PEG5k DNA nanoparticles effectively silenced a tumor-specifi c transgene (fi refl y luciferase) following direct injection into mouse intracranial gliomablastoma. Toxicity and histological analysis showed no evidence of acute or delayed infl ammatory responses. Our results demonstrate the utility of using this DNA nanoparticle-based technology for delivering genes to tumor cells as a possible therapeutic approach for patients with brain cancer. Animal models of disease have been invaluable in elucidating the molecular origins of pathogenesis, progression of disease, and the development of therapeutic interventions. However, signifi cant challenges can be encountered quantifying appropriate therapeutic biomarkers in vivo particularly in long-term experiments. Ultimately, evaluating the amelioration of disease often requires terminal endpoint analysis. The advent of light-emitting transgenic (LET) mice that contain a luciferase reporter gene conditionally activated by specifi c transcription factors produce measurable light emission as a surrogate for cell signaling and gene activation in living animals. However, germ-line transgenesis results in the insertion of the bioresponsive luciferase expression cassette into every cell of the body, which can result in substantial off-target or non-specifi c activity. Many gene therapies are targeted toward a single tissue or organ and so the effi cacy of LET can be compromised by luminescence from organs not targeted by the gene therapy. Here, we describe a novel technology whereby lentiviral-mediated delivery of a bicistronic luciferase reporter construct into neonatal rodents results in tissuespecifi c, lifetime bioresponsive activity of the reporter taking a fraction of the time and cost required to generate and establish LET mouse colonies. Tissue targeting is achieved by combining of lentiviral pseudotype and choice of administration route and is amenable to long-term, longitudinal therapeutic studies in rodents. Furthermore, our vectors can be applied to established gene knockout rodent models to quantify biomarkers of therapy in living animals increasing data quality, continuity and thus reducing cohort sizes. We have designed, generated and validated a library of 15 lentiviral vectors that are activated by transcription factors implicated in infl ammatory and fi brotic diseases and cancer. As proof of concept, we show the utility of somatotransgenic bioimaging in vivo using LPS-induced NF-κB activation as a model of infl ammation targeting the brain, lungs, liver and skin of mice and demonstrate that this response is completely absent in TLR4 knockout mice. We present evidence that this is an effective platform for therapeutic evaluation by showing depletion of this LPS-induced response by co-administration of an anti-infl ammatory corticosteroid analogue, dexamethasone, in mouse livers. We have also shown predictive responses using somatotransgenic bioimaging to oxygen-sensing (HIF activity in brain and liver), growth factors and surgical induction of disease (Smad2/3 activity in the liver). Collectively, we demonstrate the An intrathecal (IT) route of delivery is essential for pharmacotherapy of nervous system disorders. While the IT space can be easily accessed by lumbar puncture, chronic conditions, such as chronic pain or spasticity, often require long-term administration of therapeutic agents through an implanted IT catheter. Chronic IT catheterization suffers from multiple limitations, including high cost of the IT pumps, risk of infection, and unsuitability to deliver agents which do not possess the highly stable and concentrated formulation necessary for IT use. Gene therapy stands out as a feasible approach to achieve high concentrations of therapeutic agents in the cerebrospinal fl uid (CSF) without the need for chronic IT catheterization. Recent studies demonstrated the effi cacy of gene transfer to the brain and spinal cord of multiple large animal models by adeno-associated virus (AAV) serotypes 9, 7, and 2.5. IT administration of those serotypes, however, led to widespread transduction of the neural parenchyma, which is not desirable if the secretion of a therapeutic transgene product to the CSF is sought. No studies have so far investigated the feasibility of AAV-based gene therapy attaining therapeutic-range concentrations of a secreted transgene product in the CSF of a large animal model. The present study investigated IT administration of AAV8 -a serotype known to selectively target the peripheral nervous system in rodents -in a porcine model of IT drug delivery. Administration of 3.5x10 12 genome copies (GC) of AAV8 expressing enhanced green fl uorescent protein (EGFP) in pigs confi rmed the lack of central nervous system penetration by AAV8. EGFP expression in pigs was limited to the primary sensory-and motor neurons and the meninges. Next, AAV8 expressing human IL-10 (hIL-10), an analgesic cytokine with a target therapeutic range previously established in rodents, was given IT at doses ranging between 3.5x10 12 and 9x10 11 GC. Administration of AAV8/hIL10 resulted in high levels of hIL-10 in the CSF, with peak levels reaching 90 pg/ml and thereby exceeding the levels previously found to be analgesic in rodents by 1000-fold. The use of human IL-10 in pigs led to an immune response against the xenogeneic transgene, as documented by a rise of anti-hIL-10 antibodies both IT and systemically, with a time-course coinciding with a decline of hIL-10 CSF levels. Studies using AAV8 encoding porcine IL-10 are currently being performed to validate this approach using a species-specifi c version of the transgene. The present study demonstrates the capacity of IT AAV8 to achieve therapeutically signifi cant concentration of hIL-10, a secreted transgene product, in the CSF of a large animal species. The results provide support for further development of this platform for IT delivery of therapeutic agents by gene transfer.
Somatotransgenic Bioimaging: Modelling Disease Progression or Therapeutic Amelioration

Intrathecal AAV8 in Pigs: A Platform for Gene Therapy of Disorders Requiring High Levels of Therapeutic Agents in the Cerebrospinal Fluid
Inhibition of miR-124 Using AAV Sponge Vectors Leads To Enhanced Neuronal Function in the Adult Mouse Brain
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The non-coding family of microRNAs (miRNAs) are known to have important roles in large gene networks, including in that of neurons and other cells of the brain. In this study, we sought to study the function of the brain-enriched miRNA miR-124.
To this end, so-called miRNA sponges targeted at miR-124 were delivered to hippocampal neurons of adult mice using AAV5 vectors. This vector delivery resulted in the inhibition of miR-124 and thus increased the expression of predicted miR-124 targets that were involved in axonal morphogenesis and organisation. Furthermore, downstream genes that were up-regulated after miR-124 inhibition were enriched for gene ontology terms such as learning, memory and synaptic plasticity.
The results on altered learning and plasticity were strengthened after behavioural testing analysis. These studies showed enhanced hippocampal-dependent spatial memory function in a water maze task. Furthermore, the working memory capacity in a spontaneous alternation task was enhanced in mice with inhibited miR-124 function.
We further studied the mode-of-action of the miR-124 sponges using RNA-interacting protein immunoprecipitation (RIP) on samples from mouse hippocampi. This analysis showed that the miR-124 sponge sequence was incorporated into the RISC and caused only mild down-regulation of miR-124, in accordance with previous studies.
Together, these data establish miR-124 as a repressor of neuronal plasticity and function. The delivery of miR-124 sponges shows promise for future use in treatments of neurological diseases that involve cognitive defects. GM1-gangliosidosis is a lysosomal storage disorder caused by defi ciency in the enzyme acid β-galactosidase (βgal), resulting in accumulation of GM1 ganglioside in the CNS, massive neurodegeneration and premature death. We injected GM1 mice (βgal-/-) bilaterally in the thalamus with an AAVrh8 vector encoding mouse βgal (AAVrh8-mβgal), and assessed impact on lysosomal storage in CNS via Filipin staining of tissue sections. As expected lysosomal storage was reduced dramatically in most brain regions and correlated with presence of active βgal as assessed by X-gal staining. Unexpectedly large numbers of Filipin-positive cells remained in the injected structure, which also displays the most intense staining for βgal activity. Interestingly we found large numbers of Filipinpositive cells in thalamus of AAV-injected βgal+/-mice, which are otherwise normal and devoid of histological or biochemical evidence of lysosomal storage. Suggesting that presence of lysosomal storage at injection site is a de novo event rather than lack of effi cacy, and likely to be an alteration induced in AAV transduced cells. Original AAV vector mβgal was expressed under a CBA promoter (CMV enhancer, chicken beta actin promoter, hybrid intron) and carried a WPRE element. We constructed several AAV vectors with decreasing levels of transgene expression by removing promoter elements and WPRE to determine if this change related to mβgal expression levels. We also designed a vector identical to the initial, but encoding for an active site mutant of mβgal (mβgalmut) to distinguish between deleterious effects from elevated enzyme activity vs overproduction of protein targeted to the lysosomal. To control for AAVrh8 capsid responses, we included a transgene-empty vector as well as PBS injected animals. All AAVrh8 vectors were infused bilaterally in thalamus (3.4e9 total vg) of 6-8wk βgal+/-mice, at 6wk PI histological and microarray analysis of injection site was performed. Results showed almost no difference in PBS vs transgene-empty groups in Filipin with negative/ very small puncta and limited transcriptional changes. As expected, of vectors encoding wild type mβgal, AAVrh8 with CBA promoter and WPRE showed the largest effect on Filipin-positive cells, and
AAV-Mediated Gene Delivery of a Lysosomal Enzyme to CNS Induces Expression Level-Dependent Transcriptional Changes in Target Structures
